A new study published in the April 16 edition of The Oncologist reveals that the majority of gastric cancers harbor at least one clinically relevant genomic alteration, demonstrating the utility of comprehensive genomic profiling to match patients to targeted therapy options and relevant clinical trials. Gastric …

A research article titled, “Personalized genomic analyses for cancer mutation discovery and interpretation” was published yesterday in the Science Translational Medicine. In brief, the research asserts that matched tumor and normal DNA from the same patient is necessary to prevent an unacceptably high number of false …

A study authored by Julia Elvin, M.D., Ph.D., associate medical director & senior pathologist at Foundation Medicine, utilized FoundationOne®, a comprehensive genomic profile, to identify a high frequency of clinically relevant genomic alterations in recurrent, treatment refractory endometrioid endometrial …

Foundation Medicine’s vice president of corporate communications & government affairs, Sue Hager, joined a lively panel discussion at the MassBio Annual Meeting on March 26, 2015 titled “Precision Medicine: Who’s Paying?” President Obama’s Precision Medicine Initiative earmarked $215 million in the 2016 budget for …

At the recent Genitourinary Cancers Symposium, new data was presented by Dr. Sumanta Pal, Co-Director of the Kidney Cancer Program at the City of Hope Cancer Center, on behalf of lead investigator Jeffrey S. Ross, MD, Chairman of Pathology at Albany Medical College and Medical Director at Foundation Medicine, showing …

Foundation Medicine published new data today in the inaugural issue of JAMA Oncology. The peer-reviewed paper titled, “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site Reveals New Routes to Targeted Therapies” details data from a retrospective study of 200 individuals diagnosed with cancer of …

President Obama’s State of the Union address last week flashed an encouraging spotlight on the topic of Precision Medicine. We believe his comments hold both the promise and the power to accelerate research and development activities in precision medicine, and to accelerate access to novel therapies for millions of …

Today marks a meaningful milestone for molecular oncology and an important step forward towards delivering precision medicine, a theme of President Obama’s State of the Union Address this week, to many more patients with cancer. Palmetto GBA, a Medicare administrative contractor (MAC) and emerging thought leader in …

We’re pleased to participate for a second year in the World Economic Forum in Davos, Switzerland. The agenda for this year: Addressing profound political, economic, social and, above all, technological transformations resulting in a new global context for decision-making. The World Economic Forum’s Annual Meeting …

At this year’s Annual Meeting of the American Society of Hematology (ASH), Foundation Medicine and collaborators are presenting 12 abstracts that demonstrate the impact of FoundationOne® Heme across the continuum of cancer care: from diagnosis, to treatment, to contributing to the understanding of hematologic …